Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GALR1 | P47211 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533046 | 1.00 | PTPN1 (0.44) | PTPN1BRD4HTTALDH1A1LMNA | |
| SCHEMBL728537 | 0.89 | PTPN1 (0.46) | PTPN1BRD4HTTALDH1A1LMNA | |
| SCHEMBL5743345 | 0.78 | KEAP1 (0.38) | HTTALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL678414 | 0.75 | ALOX5 (0.43) | ALDH1A1LMNAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL31678641 | 0.75 | ALDH1A1 (0.39) | BRD4ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL29656653 | 0.75 | ALDH1A1 (0.43) | BRD4ALDH1A1MAPTHSD17B10POLB | |
| SCHEMBL14124657 | 0.75 | GAA (0.43) | ALDH1A1MAPTSMN1; SMN2GAAGALR1 | |
| SCHEMBL3734647 | 0.75 | ALDH1A1 (0.43) | BRD4ALDH1A1MAPTHSD17B10POLB | |
| SCHEMBL11116210 | 0.75 | PTPN1 (0.44) | PTPN1BRD4ALDH1A1MAPTKDM4E | |
| SCHEMBL28777035 | 0.73 | GRM2 (0.46) | PTPN1BRD4HTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119075-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-114269735-B | Dihydro-or tetrahydroquinazoline compound, intermediate thereof, preparation method and application | 南京创济生物医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| CN-114269735-A | Dihydro or tetrahydro quinazoline compound and intermediate, preparation method and application thereof | 南京创济生物医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021037018-A1 | DIHYDROQUINAZOLINE OR TETRAHYDROQUINAZOLINE COMPOUND AND INTERMEDIATES, PREPARATION METHODS AND USE THEREOF | 南京创济生物医药有限公司 | 2021-03-04 | — | — | WO | disclosed |
| WO-2021037018-A1 | DIHYDROQUINAZOLINE OR TETRAHYDROQUINAZOLINE COMPOUND AND INTERMEDIATES, PREPARATION METHODS AND USE THEREOF | 南京创济生物医药有限公司 | 2021-03-04 | — | — | WO | disclosed |
| CN-112119075-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-22 | — | — | CN | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | PTPN1 3203/4885BRD4 417/4885HTT 3961/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PTPN1 3203/4885BRD4 417/4885HTT 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.